ERBB2 and breast carcinoma: Nevertheless, the electrochemical immunosensor is still suitable for the clinical detection of HER-2 biomarkers both in healthy individuals (HER-2 between 2–15 ng mL−1) and in women with breast cancer (HER-2 > 15 ng mL−1).